Company Filing History:
Years Active: 2004
Title: **Daniel Verral, II: Innovator in Chiral Chromane Production**
Introduction
Daniel Verral, II is a notable inventor based in Midland, MI, with a focus on innovative methods in chemical production. His expertise lies in creating valuable chiral compounds, showing significant potential in the pharmaceutical industry.
Latest Patents
Daniel Verral, II holds a patent for "Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor." This inventive process includes novel techniques for producing chromane compositions that are enriched in at least one enantiomer, specifically chroman-2-yl carboxylic acid compounds and their esters. These compounds serve as vital intermediates in developing platelet aggregation inhibitors and demonstrate themselves as effective agents in this area. Additionally, the patent outlines enzymatic processes for resolving chiral intermediates to achieve desired enantiomers, emphasizing his contributions to advancements in chiral chemistry.
Career Highlights
Currently, Daniel Verral, II is associated with Eli Lilly and Company, a leading pharmaceutical firm recognized for its commitment to innovation and health care advancements. His work at Eli Lilly highlights the company's dedication to developing new therapeutic solutions through cutting-edge research and invention.
Collaborations
Throughout his career, Daniel has had fruitful collaborations with colleagues such as Barbara S Briggs and James P Kanter. These partnerships reflect the collaborative nature of scientific research, where diverse expertise comes together to drive innovation.
Conclusion
Daniel Verral, II represents a significant figure in the field of chemistry, particularly in producing chiral compounds essential for medical applications. His patent on chiral chromanes showcases his innovative spirit and contributes to the ongoing advancements in the pharmaceutical industry. As he continues his work at Eli Lilly and Company, the impact of his inventions is expected to resonate within the field, enhancing therapeutic options for patients worldwide.